Sign In
Buy NARI
$79.97
+0 (+0%)
At Close: May 16, 2025
Inari Medical, Inc. (NARI) Loses -27.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Monday, 06'th Nov 2023
Inari Medical, Inc. (NARI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
01:32pm, Friday, 03'rd Nov 2023
Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.
Inari Medical to Present at Upcoming Investor Conferences
04:01pm, Thursday, 02'nd Nov 2023
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from
Inari Medical, Inc. (NARI) Q3 2023 Earnings Call Transcript
11:27pm, Wednesday, 01'st Nov 2023
Inari Medical, Inc. (NASDAQ:NARI ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants John Hsu - VP, IR Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - CMO Conf
3 Solid Stocks to Buy for Superb Earnings Acceleration
07:31am, Wednesday, 18'th Oct 2023
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.
Inari Medical to Announce Third Quarter 2023 Financial Results
04:01pm, Wednesday, 11'th Oct 2023
IRVINE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from
Reasons to Add Inari Medical (NARI) Stock to Your Portfolio
09:46am, Friday, 06'th Oct 2023
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
4 Stocks That Exhibit Solid Earnings Acceleration
09:01am, Friday, 06'th Oct 2023
Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.
Inari Medical to Present at Upcoming Investor Conferences
04:01pm, Thursday, 24'th Aug 2023
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from
Wall Street Analysts See a 36.39% Upside in Inari Medical, Inc. (NARI): Can the Stock Really Move This High?
11:30am, Thursday, 10'th Aug 2023
The consensus price target hints at a 36.4% upside potential for Inari Medical, Inc. (NARI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y
10:32am, Friday, 04'th Aug 2023
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Why Shares of Inari Medical Are Up Thursday
02:26pm, Thursday, 03'rd Aug 2023
The medical device maker boosted its revenue and returned to the black on net income. Management said it benefited from the launch of two new products.
Inari Medical, Inc. (NARI) Q2 2023 Earnings Call Transcript
10:10pm, Wednesday, 02'nd Aug 2023
Inari Medical, Inc. (NASDAQ:NARI ) Q2 2023 Earnings Call Transcript August 2, 2023 4:30 PM ET Company Participants John Hsu - Vice President of Investor Relations Drew Hykes - President and CEO Mitch
Inari Medical, Inc. (NARI) Tops Q2 Earnings and Revenue Estimates
06:43pm, Wednesday, 02'nd Aug 2023
Inari Medical, Inc. (NARI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.19 per share a year ago.
Inari Medical: Approaching Interesting Levels
06:06am, Monday, 31'st Jul 2023
Shares of Inari Medical have been lagging after seeing strong momentum post its IPO in 2020. The reversal of the share price looks interesting as topline growth has continued, albeit margins have take
